BioRestorative Therapies

BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society (ORS) 2024 Annual Meeting

Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved"

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

Roth MKM Analyst Projects An Impressive Price Target Of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says "Low Valuation Undeserved"

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform – Insights From The Discussion

BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares

Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform – Insights From The Discussion

BioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York State

BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities

BioRestorative Therapies Recent News

Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It

Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise.

A Cure For Back Pain? Phase II Clinical Trials Begin For Promising Drug Candidate

Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, was recently interviewed by Benzinga. Dr. Lipetz is currently assisting BioRestorative Therapies, Inc (NASDAQ: BRTX) in phase 2 trials of a novel therapy for degenerative disc disease, BRTX-100.

A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ: BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market

Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike.

BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion

BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome with another patent notice of allowance from the United States Patent Office, adding to its already

What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?

Successful Autologous Cell-Based Therapies

BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome

Metabolism is the chemical process whereby the body produces energy from food. By breaking down carbohydrates and fats into sugars, the cells access fuel that can be used or stored via the liver or body fat. A metabolic disorder can occur when the body's chemical reactions become abnormal.

BioRestorative Therapies: This Biopharma Company Is Helping Your Body Heal Itself

Lance Alstodt, Chairman and CEO of BioRestorative Therapies, Inc. (NASDAQ: BRTX), was recently interviewed by Benzinga.

BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes

BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company focused on stem cell-based therapies, announced on the 8th of February that the European Patent Office had issued a notice of allowance for a patent application related to its metabolic ThermoStem® program.

BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results

Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony discs in the lower back. While its exact cause is unknown, factors such as age, obesity, poor posture, and overuse of the lumbar spine are believed to be contributing factors.

2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies

BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development.

The NIH Has Given BioRestorative Therapies A Stamp Of Approval

BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.

See What's Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!

While stem cell therapy has always been a more controversial topic, as the general public has gained more knowledge on the practice and induced pluripotent stem (iPS) cells have gained traction in place of human embryonic stem (hES) cells, the conversation has shifted more from the ethical concerns to the logistical concer

A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field

Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems.

Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst

In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion.

Giving Metabolism A Boost? BioRestorative Uses Science Surrounding Brown Fat Cells To Provide A Possible Breakthrough In Metabolic Disorders

In 2017, 41.9% of Americans experienced some level of obesity. Adults experiencing obesity in 2019 spent an average of $1,861 more on medical expenses than people with a healthy weight.

This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence

BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective, safe and capable of generating long-term relief.